In a statement issued on 01/02/2017 Roth Capital upped the price target of Cempra (NASDAQ:CEMP) to $2.50 reporting a potential downside of -0.11%.

On Friday December 30, 2016, Roth Capital released a statement for Cempra (NASDAQ:CEMP) raised the target price from $0.00 to $2.50. At the time, this indicated a possible downside of -0.04%.

Just yesterday Cempra (NASDAQ:CEMP) traded 7.69% higher at $2.80. The company’s 50-day moving average is $6.55 and its 200-day moving average is $16.91. With the last close down -83.45% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.04% over the date range. Volume of trade was up over the average, with 19,560,884 shares of CEMP changing hands over the typical 2,761,170

See Chart Below

Cempra has 52 week low of $2.55 and a 52 week high of $30.20 and has a total market value of $0.

A total of 12 brokerages have released a ratings update on CEMP. Five equity analysts rating the company a strong buy, 6 brokers rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $38.75.

Brief Synopsis About Cempra (NASDAQ:CEMP)

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

The post A Statement Released Earlier today by Roth Capital about Cempra (NASDAQ:CEMP) raises the target price to $2.50 appeared first on Octafinance.